ETHIOPIA -- Inactivated Polio Vaccine (IPV) Support
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ethiopia
2. Grant Number: 1518-ETH-25c-X / 15-ETH-08h-Y
3. Date of Decision Letter: 01 July 2014
4. Date of the Partnership Framework Agreement: 23 July 2013
5. Programme Title: NVS, IPV Routine
6. Vaccine type: Inactivated Polio Vaccine (IPV)
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID
8. Programme Duration: 2015 - 2018
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI's review and approval processes.

<table>
<thead>
<tr>
<th>Program Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>Total$3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$1,448,500</td>
<td>US$5,646,000</td>
<td>US$7,094,500</td>
</tr>
</tbody>
</table>

10. Vaccine Introduction Grant: US$2,536,500

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with GAVI funds in each year</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>1,210,200</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>798,700</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>8,800</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$1,448,500</td>
</tr>
</tbody>
</table>

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the programme.
3 This is the total amount endorsed by GAVI for 2015 and 2016.
4 This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.
12. Procurement agency: UNICEF.

13. Self-procurement: Not applicable.

14. Co-financing obligations:
   GAVI's usual co-financing requirements do not apply to IPV. However, Ethiopia is
   encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: N/A

16. The Country shall deliver the following documents by the specified due dates as part of
   the conditions to the approval and disbursements of the future Annual Amounts: The
   Country shall deliver the following documents by the specified due dates as part of the
   conditions to the approval and disbursements of the future Annual Amounts.

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with GAVI Secretariat</td>
</tr>
</tbody>
</table>

17. Financial Clarifications: Not applicable.

18. Other conditions: If Ethiopia envisages a switch in product presentation, it is encouraged to
   incorporate elements for both IPV presentations in your initial introduction preparations, in
   order to minimise the need for later interventions and facilitate the switch. In those
   circumstances, in principle, no product switch grant will be provided to Ethiopia.

Signed by,
On behalf of the GAVI Alliance

Hind Khatib-Othman
Managing Director, Country Programmes

01 July 2014